ArticlePLOS global public health2025
Active case-finding for TB in India: Assessment of scale and quality benchmarks, time taken and use of rapid molecular diagnostic tests.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Digital tools not enough; quality control-linked incentives are needed for tuberculosis active case finding.Public health action · 2026Article
- Does active case finding detect TB early in programme settings? A national-level study in India.Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors.
Funding
Abstract
Since 2017, tuberculosis active case-finding (TB ACF) has been implemented within the routine framework of India's national TB elimination program. Symptom screen of high-risk population followed by confirmation of TB among symptom-screen positive is the algorithm. ACF scale and quality assessments hitherto were predominantly local or based on aggregate program data with limited details on all the scale and quality indicators, the time taken and the extent of use of rapid molecular diagnostic tests in ACF care cascade. In this cohort study from high-risk populations in 30 randomly sampled districts (nine states), we assessed one ACF cycle (intention to screen the high-risk population once) during January-September 2023 using prospectively collected individual level data. 581 633 high-risk individuals were screened by the program utilizing existing workforce and resources. The two scale indicators (target, observed) were: percentage of i) population mapped as high-risk (≥11%, 18.3%) and ii) mapped population screened (≥90%, 7.4%). The four quality indicators (target, observed) were: percentage of i) screened identified as presumptive TB (≥5%, 2%) ii) presumptive TB tested (≥95%, 66.3%) iii) tested diagnosed as TB (≥5%, 1.6%) and iv) diagnosed put on treatment (≥95%, 100%). The number needed to screen (target ≤1538 considering the algorithm) to detect one person with TB was 4971. The same was observed across most of the high-risk groups, with few exceptions. The extent of using rapid molecular diagnostic tests was 26.4% and the median time taken from screening to sputum collection and testing was one day. To conclude, ACF scale and quality in 2023, assessed using prospectively collected individual level data, were grossly below the benchmark and lower than previously reported (2021) based on retrospective aggregate program data. Effective planning, resource allocation including use of rapid molecular diagnostic tests and individual data recording among those screened to facilitate implementation monitoring are recommended.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.